Kyntra Bio Inc (0IL8.L)

Name: Kyntra Bio Inc Financial Statements
Creator: Quarter Results

Healthcare | Medical Pharmaceuticals

Latest reporting period: 2025-12-31

Latest Quarter

2025-12-31

Revenue

$1.3M

Net Income

-$14.2M

Operating Margin

-1,057.3%

Free Cash Flow

-$4.8M

Debt / Assets

96.3%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Kyntra Bio Inc (0IL8.L).
Income Statement (Quarterly)	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Revenue	1,278,000	1,076,000	1,348,000	2,739,000
Cost of Revenue	0	-58,000	85,000	252,000
Gross Profit	0	1,134,000	1,263,000	2,487,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	7,251,000	5,295,000	7,057,000	8,106,000
Operating Expenses	14,519,000	6,545,000	13,315,000	17,407,000
Operating Income	-13,512,000	-5,411,000	-12,052,000	-14,920,000
Interest Expense	-2,413,000	2,083,000	2,009,000	2,257,000
Income Before Tax	-14,609,000	-13,146,000	-13,775,000	-16,764,000
Income Tax Expense	-389,000	0	-92,000	2,000
Net Income	-14,220,000	200,636,000	-7,603,000	4,639,000
Per Share
EPS	-3.51	49.61	-1.88	0.05
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Kyntra Bio Inc (0IL8.L).
Income Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue	6,440,000	29,621,000	46,803,000	140,734,000
Cost of Revenue	0	15,561,000	3,962,000	20,280,000
Gross Profit	0	14,060,000	42,841,000	120,454,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	27,709,000	49,330,000	86,483,000	124,688,000
Operating Expenses	51,226,000	164,476,000	365,562,000	421,479,000
Operating Income	-45,895,000	-150,416,000	-322,721,000	-301,025,000
Interest Expense	-8,759,000	8,247,000	8,095,000	1,440,000
Income Before Tax	-58,294,000	-153,367,000	-323,222,000	-294,869,000
Income Tax Expense	-90,000	-269,000	-252,000	358,000
Net Income	183,452,000	-47,579,000	-284,232,000	-293,654,000
Per Share
EPS	45.37	-0.48	-2.92	-3.14
EPS Diluted	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Kyntra Bio Inc (0IL8.L).
Balance Sheet (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	47,872,000	50,482,000	113,688,000	155,700,000
Short Term Investments	41,106,000	0	121,898,000	266,308,000
Net Receivables	216,000	481,000	41,053,000	16,299,000
Inventory	3,743,000	3,155,000	41,565,000	40,436,000
Total Current Assets	99,073,000	196,509,000	331,559,000	492,826,000
Property Plant Equipment	0	97,000	81,372,000	100,933,000
Goodwill and Intangibles	0	0	0	0
Total Assets	119,594,000	214,525,000	423,529,000	610,087,000
Liabilities
Account Payables	3,745,000	5,064,000	17,960,000	30,758,000
Short Term Debt	0	0	14,117,000	10,328,000
Total Current Liabilities	29,242,000	133,306,000	217,668,000	273,562,000
Long Term Debt	0	90,174,000	156,338,000	16,917,000
Total Liabilities	115,119,000	398,159,999	585,728,000	611,567,000
Shareholders Equity
Retained Earnings	-1,706,047,000	-1,889,499,000	-1,841,920,000	-1,557,688,000
Total Shareholders Equity	4,475,000	-225,601,999	-204,166,000	-21,447,000

Balance sheet annual history for Kyntra Bio Inc (0IL8.L).
Balance Sheet (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	47,872,000	50,482,000	113,688,000	155,700,000
Short Term Investments	41,106,000	0	121,898,000	266,308,000
Net Receivables	216,000	481,000	41,053,000	16,299,000
Inventory	3,743,000	3,155,000	41,565,000	40,436,000
Total Current Assets	99,073,000	196,509,000	331,559,000	492,826,000
Property Plant Equipment	0	97,000	81,372,000	100,933,000
Goodwill and Intangibles	0	0	0	0
Total Assets	119,594,000	214,525,000	423,529,000	610,087,000
Liabilities
Account Payables	3,745,000	5,064,000	17,960,000	30,758,000
Short Term Debt	0	0	14,117,000	10,328,000
Total Current Liabilities	29,242,000	133,306,000	217,668,000	273,562,000
Long Term Debt	0	90,174,000	156,338,000	16,917,000
Total Liabilities	115,119,000	398,159,999	585,728,000	611,567,000
Shareholders Equity
Retained Earnings	-1,706,047,000	-1,889,499,000	-1,841,920,000	-1,557,688,000
Total Shareholders Equity	4,475,000	-225,601,999	-204,166,000	-21,447,000

Cash flow quarterly history for Kyntra Bio Inc (0IL8.L).
Cash Flow Statement (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	183,452,000	-47,579,000	-284,232,000	-293,654,000
Depreciation & Amortization	748,000	2,692,000	9,930,000	10,604,000
Stock Based Compensation	6,576,000	25,215,000	50,767,000	65,601,000
Change in Working Capital	0	-117,459,000	-119,687,000	70,430,000
Operating Cash Flow	-4,774,000	-137,999,000	-315,021,000	-145,933,000
Investing Activities
Capital Expenditure	-38,000	-266,000	-2,519,000	-3,741,000
Investments	-38,000	-266,000	-2,519,000	-3,741,000
Investing Cash Flow	35,419,000	125,993,000	153,657,000	89,116,000
Financing Activities
Debt Repayment	0	-40,000	73,594,000	-135,000
Common Stock Issued/Repurchased	0	139,000	48,407,000	-983,000
Dividends Paid	-3,947,000	-2,230,000	0	-4,764,000
Financing Cash Flow	-86,028,000	-255,000	122,749,000	46,776,000
Summary
Free Cash Flow	-4,812,000	-138,265,000	-317,540,000	-149,674,000
Net Change in Cash	-54,306,000	-11,510,000	-42,012,000	-15,523,000

Cash flow annual history for Kyntra Bio Inc (0IL8.L).
Cash Flow Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	183,452,000	-47,579,000	-284,232,000	-293,654,000
Depreciation & Amortization	748,000	2,692,000	9,930,000	10,604,000
Stock Based Compensation	6,576,000	25,215,000	50,767,000	65,601,000
Change in Working Capital	0	-117,459,000	-119,687,000	70,430,000
Operating Cash Flow	-4,774,000	-137,999,000	-315,021,000	-145,933,000
Investing Activities
Capital Expenditure	-38,000	-266,000	-2,519,000	-3,741,000
Investments	-38,000	-266,000	-2,519,000	-3,741,000
Investing Cash Flow	35,419,000	125,993,000	153,657,000	89,116,000
Financing Activities
Debt Repayment	0	-40,000	73,594,000	-135,000
Common Stock Issued/Repurchased	0	139,000	48,407,000	-983,000
Dividends Paid	-3,947,000	-2,230,000	0	-4,764,000
Financing Cash Flow	-86,028,000	-255,000	122,749,000	46,776,000
Summary
Free Cash Flow	-4,812,000	-138,265,000	-317,540,000	-149,674,000
Net Change in Cash	-54,306,000	-11,510,000	-42,012,000	-15,523,000